Results 171 to 180 of about 132,496 (204)
Some of the next articles are maybe not open access.
Pharmacogenetics of acute lymphoblastic leukemia
Current Opinion in Hematology, 2004The outcome in children with acute lymphoblastic leukemia has improved significantly over the past four decades. Current therapy results in event-free survival exceeding 80% for most patients. The development of risk-adapted therapy based on characteristics of the child (age), leukemia (leukocyte count, acquired genetic characteristics) and early ...
Stella M. Davies, Parinda A. Mehta
openaire +3 more sources
Pharmacogenomics of acute lymphoblastic leukemia
Current Opinion in Hematology, 2006The cure rate in children with acute lymphoblastic leukemia now exceeds almost 80% in most treatment protocols in industrialized countries. This has mainly been achieved empirically through carefully controlled, randomized clinical trials. Due to relative nonspecific action and narrow therapeutic indices of antileukemic medications, however, current ...
William E. Evans, Leo Kager
openaire +3 more sources
Acute lymphoblastic leukemia in adults
Current Treatment Options in Oncology, 2000The therapy of acute lymphoblastic leukemia (ALL) in adults has built on the remarkable success achieved in the treatment of this disease in children. However, older age and other adverse risk factors seen more commonly in adults than in children have lessened the success of the treatment of ALL in comparison with what has been achieved in children ...
openaire +3 more sources
Acute Lymphoblastic Leukemia of Childhood
Hematology/Oncology Clinics of North America, 1987Over the last 20 years, the rate of long-term disease-free survival of childhood acute lymphoblastic leukemia increased from less than 1 to 60 per cent. Strategies for disease control include (1) intensive multiagent induction to rapidly decrease the tumor burden and minimize the chance of emergence of a resistant population of cells, (2) restoration ...
openaire +3 more sources
Acute lymphoblastic leukemia in children
Current Opinion in Oncology, 2000As the overall long-term event-free survival rate in children with acute lymphoblastic leukemia approaches 80%, emphasis is being placed on risk-directed therapy so that patients are neither overtreated nor undertreated. It has become apparent that a risk assignment system based on primary genetic abnormalities is inadequate by itself.
openaire +3 more sources
Acute lymphoblastic leukemia in infancy
Pediatric Blood & Cancer, 2007Infant ALL is uncommon, biologically distinctive from the disease in older children, and associated with a relatively poor prognosis. Adverse prognostic factors include the presence of an MLL gene rearrangement (observed in up to 80% of infants with ALL), younger age at diagnosis, high presenting leukocyte counts, and slow early response to therapy ...
openaire +3 more sources
Acute Lymphoblastic Leukemia: Background
2003Acute lymphoblastic leukemia is a fascinating disease for the cytogeneticist, as so many cases have a clone detectable by cytogenetics or FISH, and because identifying the abnormalities provides such useful information to the clinician. However, it is also a frustrating disease, as it has technical challenges such as a marked tendency for the sample to
openaire +2 more sources
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly